Skip to main content
. 2015 Sep 14;112(39):12005–12010. doi: 10.1073/pnas.1515882112

Fig. 4.

Fig. 4.

HPB enhances anticancer effects of SAHA in mice bearing human prostate cancer CWR22 xenograft. (A) HPB is well tolerated in mice. Mice were injected with indicated doses of HPB i.p. daily for 5 d. Data are represented as mean ± SD (P < 0.001). The P value was derived from the two-way ANOVA. (B) HDAC6 selectivity of HPB in spleen isolated from mice. Spleens were isolated from mice injected with indicated drugs at 1.5, 3, and 5 h after last injection on day 5. Immunoblots for acetylated tubulin (Acet-Tub) and acetylated histone H3 (Acet-H3). HSP90 and total H3 are loading controls. (C) Weights and tumor volumes of mice were injected with HPB (300 mg/kg) i.p. daily for 5 d a week, paclitaxel (1.5 mg/kg) i.p. once a week, or combination treatment over 4 wk. (D) Immunoblots of mice treated with DMSO vehicle solvent, 1.5 mg/kg paclitaxel, HPB (100 or 300 mg/kg), and combination treatment. Total H3 is a loading control. (E) Immunoblots of all mice treated with 300 mg/kg HPB alone or 1.5 mg/kg paclitaxel alone. Total H3 is a loading control.